Beyond fulfilment

Contact Us

Abcur AB is the Nordic division of ADVANZ PHARMA. We focus on the development, registration and marketing of a wide range of niche prescriptions within the Nordic markets’ vital therapeutic indications, including intensive care, pain management, ophthalmology, endocrinology and anaesthesia.

Our products are manufactured according to Good Manufacturing Practice (GMP) and European law by certified manufacturers, as well as in accordance with European environmental requirements to ensure the delivery of high-quality products.

We are continuously seeking to expand our product portfolio within existing therapeutic areas and where we see possibilities in new areas.

Image for Concordia International corp. provides further update on its recently completed recapitalization transaction and the issue price of its private placement

Press Releases — 12 Sep 2018

Further update provided on recently completed recapitalization transaction and the issue price of its private placement

As described in the Company's management information circular dated May 15, 2018, and previous press releases issued in connection with the Recapitalization Transaction, the terms of the Recapitalization Transaction and the CBCA Plan, including the terms and US$13.69 issue price of the Private Placement, were extensively negotiated among the Company, holders of its secured debt, holders of its unsecured debt, the participants in the Private Placement, and their respective advisors.
Learn more